Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries by Foo, Jason et al.
University of Kentucky
UKnowledge
Preventive Medicine and Environmental Health
Faculty Publications Preventive Medicine and Environmental Health
4-19-2016
Continuing to Confront COPD International
Patient Survey: Economic Impact of COPD in 12
Countries
Jason Foo
GlaxoSmithKline, UK
Sarah H. Landis
GlaxoSmithKline, UK
Joe Maskell
GlaxoSmithKline, UK
Yeon-Mok Oh
University of Ulsan, South Korea
Thys van der Molen
University of Groningen, The Netherlands
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/pmeh_facpub
Part of the Environmental Public Health Commons
This Article is brought to you for free and open access by the Preventive Medicine and Environmental Health at UKnowledge. It has been accepted for
inclusion in Preventive Medicine and Environmental Health Faculty Publications by an authorized administrator of UKnowledge. For more
information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Foo, Jason; Landis, Sarah H.; Maskell, Joe; Oh, Yeon-Mok; van der Molen, Thys; Han, MeiLan K.; Mannino, David M.; Ichinose,
Masakazu; and Punekar, Yogesh, "Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12
Countries" (2016). Preventive Medicine and Environmental Health Faculty Publications. 42.
https://uknowledge.uky.edu/pmeh_facpub/42
Authors
Jason Foo, Sarah H. Landis, Joe Maskell, Yeon-Mok Oh, Thys van der Molen, MeiLan K. Han, David M.
Mannino, Masakazu Ichinose, and Yogesh Punekar
Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries
Notes/Citation Information
Published in PLOS ONE, v. 11, no. 4, e0152618, p. 1-15.
© 2016 Foo et al.
This is an open access article distributed under the terms of the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author
and source are credited.
Digital Object Identifier (DOI)
https://doi.org/10.1371/journal.pone.0152618
This article is available at UKnowledge: https://uknowledge.uky.edu/pmeh_facpub/42
RESEARCH ARTICLE
Continuing to Confront COPD International
Patient Survey: Economic Impact of COPD in
12 Countries
Jason Foo1, Sarah H. Landis2, Joe Maskell2, Yeon-Mok Oh3, Thys van der Molen4, MeiLan
K. Han5, David M. Mannino6, Masakazu Ichinose7, Yogesh Punekar8*
1 Health Outcomes, GlaxoSmithKline, Uxbridge, United Kingdom, 2 GlaxoSmithKline, Real World Evidence,
Uxbridge, United Kingdom, 3 University of Ulsan College of Medicine, Asan Medical Centre, Seoul, South
Korea, 4 University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands,
5 Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, Michigan, United States of
America, 6 University of Kentucky College of Public Health, Lexington, Kentucky, United States of America,
7 Tohoku University Graduate School of Medicine, Sendai, Japan, 8 GlaxoSmithKline, Value Evidence
Outcomes, Uxbridge, United Kingdom
* yogesh.q.punekar@gsk.com
Abstract
Background
The Continuing to Confront COPD International Patient Survey estimated the prevalence
and burden of COPD across 12 countries. Using data from this survey we evaluated the
economic impact of COPD.
Methods
This cross-sectional, population-based survey questioned 4,343 subjects aged 40 years
and older, fulfilling a case definition of COPD based on self-reported physician diagnosis or
symptomatology. Direct cost measures were based on exacerbations of COPD (treated
and those requiring emergency department visits and/or hospitalisation), contacts with
healthcare professionals, and COPDmedications. Indirect costs were calculated from work
loss values using the Work Productivity and Activity Impairment scale. Combined direct and
indirect costs estimated the total societal costs per patient.
Results
The annual direct costs of COPD ranged from $504 (South Korea) to $9,981 (USA), with
inpatient hospitalisations (5 countries) and home oxygen therapy (3 countries) being the
key drivers of direct costs. The proportion of patients completely prevented from working
due to their COPD ranged from 6% (Italy) to 52% (USA and UK) with 8 countries reporting
this to be20%. Total societal costs per patient varied widely from $1,721 (Russia) to
$30,826 (USA) but a consistent pattern across countries showed greater costs among
those with increased burden of COPD (symptoms, health status and more severe disease)
and a greater number of comorbidities.
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Conclusions
The economic burden of COPD is considerable across countries, and requires targeted
resources to optimise COPDmanagement encompassing the control of symptoms, preven-
tion of exacerbations and effective treatment of comorbidities. Strategies to allow COPD
patients to remain in work are important for addressing the substantial wider societal costs.
Introduction
Chronic obstructive pulmonary disease (COPD) is a multifactorial and heterogeneous disease
[1,2], and a global health problem afflicting millions of people worldwide [3]. It is characterised
by persistent and progressive airflow limitation, the severity of which is affected by exacerba-
tions of COPD and the presence of comorbid conditions [1]. In 2010, The Global Burden of
Disease Study ranked COPD as the third leading cause of mortality and the ninth leading cause
of disability-adjusted life years lost [4,5].
The substantial burden of COPD is associated with a significant economic impact both in
terms of direct (healthcare and medical) and indirect (impact on home and work productivity)
costs [1]. Previous international surveys have reported significant economic consequences of
COPD across many developed and developing countries [6–8]. In the original Confronting
COPD International Survey in North America and Europe the majority of direct costs across
countries were associated with hospitalizations and medication costs [6]. In that study, annual
societal costs were greater in patients with more severe disease and in those who reported
comorbidities. Similarly, the BREATHE study, conducted in 11 countries across the Middle
East, North Africa, and Pakistan, reported increased medical resource use in association with
more severe disease, exacerbations of COPD, a higher COPD assessment Test (CAT) score and
the presence of comorbidities [7]. In the COPD Uncovered International Survey of a working
age population with COPD, work productivity and the level of work impairment was worse
with increasing age and disease severity, and respondents reporting a greater number of
comorbidities were more likely to retire early [8]. Data generated from these types of studies
are important for understanding the true economic burden of COPD and may have important
implications for targeting resources and informing public health policies [9].
The Continuing to Confront COPD International Patient Survey was conducted globally
across 12 countries as a follow-up of the original Confronting COPD International Survey
[10], and estimated the prevalence and burden of COPD [11]. This paper presents the analysis
of the cost associated with COPD from the Continuing to Confront COPD International
Patient Survey, including the direct and indirect costs of COPD and represents one of the larg-
est global cost of COPD evaluations to date.
Materials and Methods
The study design and methodology of the Continuing to Confront COPD International Patient
Survey have been reported previously [11]. This was a population-based, cross-sectional survey
of adults 40 years and older who fulfilled a case definition of COPD by meeting one of the fol-
lowing criteria: 1) a physician diagnosis of COPD/emphysema, 2) a physician diagnosis of
chronic bronchitis, or 3) a symptom-based definition of chronic bronchitis, plus either regular
use of respiratory medication for their condition or chronic cough with phlegm most days. The
survey was conducted between November 2012 and May 2013. Participation in the survey was
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entirely voluntary and confidential, and all subject data were anonymous. Prior to completion
of the survey, all respondents were informed that they could terminate the interview at any
time and their verbal consent to participate was recorded as part of the survey procedures. The
survey protocol and consent procedure were reviewed by the Abt SRBI Institutional Review
Board (IRB) (registered with the Office for Protection from Research Risks, Health and
Human Services) and granted an IRB exemption as the criteria for exemption under 45 CFR
46.101(b)(2) of the United States Code of Federal Regulations were met.
Patients from 12 countries (Brazil, France, Germany, Italy, Japan, Mexico, the Netherlands
[NL], Russia, South Korea [SK], Spain, the United Kingdom [UK], and the United States of
America [USA]) provided responses to a structured questionnaire either by telephone or in
face-to-face interviews. Patients were asked about their disease severity, symptoms, medica-
tions and COPD-related healthcare resource use (including hospitalisations, emergency
department (ED) visits, and healthcare professional consultations). Several patient-reported
instruments were completed including modified Medical Research Council (mMRC) Dys-
pnoea Scale [12], and the COPD Assessment Test (CAT) [13]. Patients were also questioned
about their work loss due to COPD and completed the Work Productivity and Activity
Impairment Questionnaire (WPAI) which measures impacts on work as a result of poor health
[14]. Higher percentages indicate greater impairment and less productivity.
Statistical analysis
A societal perspective was used which included COPD-related healthcare resource use and lost
productivity. Costs were calculated using local country specific costs and converted to US dol-
lars (2013) using the average historical exchange rates over the survey period (Table A in S1
Supporting Information).
Direct costs. Direct cost measures were estimated for moderate and severe COPD exacer-
bations, contact with healthcare professionals, COPD medications, home oxygen use and influ-
enza vaccination during the past 12 months. For this analysis, exacerbations of COPD were
defined as episodes of worsening breathing problems that required treatment with antibiotics
and/or systemic corticosteroids. These were further categorized as moderate (community
treated) which were costed as a general practice visit plus a course of prednisolone 40mg once
daily for 5 days and co-amoxiclav 875mg/125mg twice a day for 7 days (in line with global
COPD guidelines1) and severe (requiring an ED visit and/or hospitalisation) which were costed
for the ED and/or inpatient stay as reported. Of note, the requirement of treatment in addition
to self reported worsening of breathing problems to define exacerbations was implemented in
this study to improve the specificity of the definition for an exacerbation. Due to this additional
requirement, the reported percentage of patients with an exacerbation episode reported herein
is slightly lower than previously reported for this survey.[11] Health care professional (HCP)
visits were based upon the medical specialty seen most often by patients in the survey (either a
GP/Specialist/Nurse) and the corresponding frequency of contact. For the 1% of HCP visits
that were recorded as ‘don’t know’ or ‘refused’, we imputed the mostly common used HCP
type from that country. In addition, if a HCP type was reported but the frequency of visiting
that HCP was missing, the average frequency data from that country were imputed. For COPD
medications, only patients that reported using a prescription medication in the past year (92%)
were included in the cost analysis (fewer than 2% reported ‘don’t know’ or refused to respond
to the medication question and there were no imputations for these data). All COPD prescrip-
tion medicines reported were grouped by drug class; it was assumed that only one drug from
the same class was taken at any time; drugs across different classes were assumed to be taken
concurrently. All medications were assumed to be taken for a full year as per the licensed dose.
Economic Impact of COPD in 12 Countries
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Antibiotics and oral/systemic corticosteroids were included in the cost of moderate exacerba-
tions and were therefore excluded from the treatment cost calculation to avoid double count-
ing. The cost for each class was calculated using a weighted average (based on market share) of
the five most commonly prescribed preparations within that class in each country (Table B in
S1 Supporting Information). Patients who indicated that they had received an influenza vacci-
nation were assumed to have received a single vaccination. For patients reporting home oxygen
use, an average annual cost for their country was applied.
The annual per patient direct costs were calculated for each healthcare resource measure, by
multiplying the frequency of use in the past year by unit costs obtained from local health eco-
nomics experts in each participating country, global datasets or local prescribing data on medi-
cation sales. Each of these costs was combined to provide an estimate of the total annual mean
direct cost of COPD per patient.
Indirect costs. Indirect costs were evaluated using the human capital approach, based on
the equivalence between the value of lost productivity and the associated annual earning for
obtaining this production [15]. Annual mean indirect costs were calculated by multiplying the
mean percent of annual work loss by the annual average income (country specific) (Table C in
S1 Supporting Information). Work loss in the week prior to the survey was estimated using
WPAI and extrapolated to the prior 12 months, and was only considered in patients of working
age (based on effective retirement age in each country (Table C in S1 Supporting Information).
Patients who reported that they were retired and were aged below the effective retirement age
for their country were assumed to have 100% work loss. As a scenario analysis, indirect costs
were also calculated using the friction cost method. This method reduces the likelihood of over-
estimating indirect costs by assuming that a patient missing work due to a long period of illness
is likely to be replaced by another employee, rather than the position remaining vacant until
the patient is able to return to work [16]. A friction period of 90 days and an elasticity correc-
tion factor of 0.8 were used for all countries as these were the most frequently reported in the
literature [17].
Total societal costs. Direct and indirect costs were combined to estimate the total annual
societal cost of COPD per patient. A sensitivity analysis of total societal costs was also con-
ducted, in which national currencies were converted into US dollars using purchasing power
parities instead of exchange rates (Table A in S1 Supporting Information).
In order to identify subgroups of patients in which the burden of COPD was disproportion-
ately high, total societal costs were compared across the following subgroups for each country:
• Breathlessness (mMRC)—mMRC 0–1, mMRC2 (moderate-to-severe dyspnoea)
• Health status (CAT)—CAT20, CAT>20 (high-to-very high impact)
• Self- perceived severity of COPD–mild, moderate, severe/very severe
• Adherence (Morisky MMAS-8)—Low adherence<6, medium adherence 6 to<8, high
adherence8
• Comorbidity—<2,2 self reported co-morbidities from a list of 6 a priori comorbidities of
clinical interest (asthma, hypertension, heart attack, heart failure, stroke, and cancer)
To minimize the effect of sex and age imbalances by country in the sampling and screening
process, the reported percentages and costs were weighted by age and sex according to the lat-
est census data available in each country.
Economic Impact of COPD in 12 Countries
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Results
Patient demographics and baseline characteristics
A total of 4,343 respondents fulfilled the case definition of COPD and consented to complete
the full survey. A total of 45% qualified with a physician diagnosis of COPD, chronic obstruc-
tive airway disease, or emphysema; 45% had a physician diagnosis of chronic bronchitis; and
10% had symptom-based chronic bronchitis. The mean age of the population ranged from 57.2
years (Russia) to 66.8 years (France), with Brazil reporting the highest proportion of patients of
working age (75%) and France reporting the lowest (31%) (Table 1). The majority of patients
in each country perceived their COPD as being mild or moderate. When COPD burden was
assessed using validated measures, the frequency of moderate to severe dyspnoea (mMRC Dys-
pnoea Scale score2) ranged from 25% in Japan to 61% in the UK, and the frequency of high-
to-very high impact on health status (CAT score>20) ranged from 34% in Japan to 72% in
Brazil. Japanese patients also had the lowest frequency of co-morbidity (16% reporting two or
more co-morbid diseases) while a third or more of patients in the USA, Brazil, Germany and
the Netherlands reported two or more comorbidities.
Healthcare resource use
With respect to COPD-related healthcare resource use, patients across all countries except
Japan and Brazil reported more frequent contact with general practitioners (GPs) than with
Table 1. Patient demographics and baseline characteristics: Continuing to Confront COPD International Patient Survey, 2012–13.
USA
n = 1,001
Mexico
n = 328
Brazil
n = 300
France
n = 300
Germany
n = 300
Italy
n = 302
Spain
n = 303
UK
n = 305
NL
n = 303
Russia
n = 301
Japan
n = 300
SK
n = 300
Female (%) 52 57 55 52 56 43 43 56 51 61 46 40
Age in
years, mean
(SD)
60.9
(10.9)
62.1
(12.2)
57.9
(12.4)
66.8
(13.6)
59.7 (11.2) 63.1
(12.8)
65.1
(12.5)
62.4
(11.3)
61.7
(11.2)
57.2
(11.1)
59.6
(12.6)
61.8
(12.2)
Working
age (%)
63 74 75 31 58 43 40 53 53 54 74 72
Self-reported COPD severity (%)
Mild 30 16 21 25 31 26 27 24 28 26 59 14
Moderate 41 56 55 57 41 56 56 41 54 67 28 53
Severe/
very severe
29 27 24 19 28 18 17 35 19 7 13 33
mMRC grade, %
0–1 42 42 40 50 58 40 49 37 65 60 69 51
2 50 50 56 43 36 47 44 61 30 38 25 46
Missing 8 8 4 8 6 13 7 3 5 2 6 3
CAT score,%
20 33 34 27 56 51 49 58 28 60 42 66 31
>20 60 66 72 42 46 49 38 66 34 56 34 69
Missing 7 0 1 2 3 2 4 7 6 2 1 0
Comorbidities, %
0–1 47 76 60 70 66 71 69 74 67 74 84 73
2 53 17 39 28 34 28 30 26 32 24 16 26
Missing 0 7 1 2 0 1 1 0 1 2 0 1
Abbreviations: CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; SD, standard deviation; mMRC, modified Medical Research
Council Scale; NL, Netherlands; South Korea, SK.
doi:10.1371/journal.pone.0152618.t001
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specialists (Table 2). The mean number of contacts with GPs in the prior 12 months ranged
from 2.6 (SD = 5.2) in Spain to 8.3 (SD = 11.9) in the UK, while specialists were seen on average
from 1.6 visits (SD = 4.4) in Russia to 5.1 visits (SD = 8.8) in Japan.
The proportion of patients reporting at least one moderate exacerbation was highest in
Mexico (75%), the UK (63%) and Italy (55%), and lowest in Brazil (31%) (Table 2). The mean
number of moderate exacerbations ranged from 1.0 (Brazil [SD = 2.0]; France [SD = 1.8]; Italy
[SD = 1.4]; and Spain [SD = 1.5]) to 4.1 (SD = 4.9) (South Korea) with the majority of individ-
ual countries reporting an approximate mean number in the range of 1–2. Mean numbers of
severe exacerbations resulting in an ED visit or hospitalisation were noticeably higher in Brazil
(mean [SD]: 1.3 [1.9] and 0.4 [1.1] respectively) compared with other countries.
Table 2. Frequency of contact with healthcare professionals and frequency of exacerbations: Continuing to Confront COPD International Patient
Survey, 2012–13.
USA
n = 1,001
Mexico
n = 328
Brazil
n = 300
France
n = 300
Germany
n = 300
Italy
n = 302
Spain
n = 303
UK
n = 305
NL
n = 303
Russia
n = 301
Japan
n = 300
SK
n = 300
General practitioner (GP) contact
Usual care
from a GP
(%)
66 74 49 78 62 70 58 81 71 80 50 54
Mean visits
per patient
(SD)
4.4 (8.0) 7.4 (9.4) 4.2 (8.3) 6.5
(10.2)
4.2 (8.5) 4.6 (7.5) 2.6 (5.2) 8.3
(11.9)
4.1
(9.0)
4.5 (7.7) 5.1
(7.7)
5.7
(10.7)
Specialist contact
Usual care
from a
specialist (%)
33 26 51 22 38 30 42 15 26 20 50 46
Mean visits
per patient
(SD)
2.4 (6.3) 2.6 (6.9) 4.0 (8.3) 2.3 (6.2) 3.3 (7.7) 2.0 (5.5) 2.8 (7.6) 2.3
(7.8)
1.7
(5.6)
1.6 (4.4) 5.1
(8.8)
4.9
(8.1)
Moderate Exacerbations1
At least one
in past year
(%)
43 75 31 40 52 55 47 63 38 52 39 52
Mean
number per
patient (SD)
1.4 (2.5) 2.7 (3.2) 1.0 (2.0) 1.0 (1.8) 1.6 (2.6) 1.0 (1.4) 1.0 (1.5) 1.9
(2.2)
1.1
(2.2)
1.4 (2.3) 2.4
(4.1)
4.1 (4.9)
Emergency department visit for exacerbation
At least one
in past year
(%)
19 21 50 9 8 6 31 18 9 19 7 3
Mean
number per
patient (SD)
0.4 (1.2) 0.5 (1.5) 1.3 (1.9) 0.2 (0.9) 0.2 (0.9) 0.1 (0.5) 0.6 (0.9) 0.4
(0.9)
0.1
(0.5)
0.5 (1.5) 0.1
(0.4)
0.1 (0.5)
Hospitalization for exacerbation
At least one
(%)
12 14 20 8 9 6 16 15 7 14 3 5
Mean
number per
patient (SD)
0.2 (0.7) 0.3 (0.8) 0.4 (1.1) 0.2 (1.1) 0.1 (0.5) 0.1 (0.3) 0.2 (0.5) 0.3
(0.9)
0.1
(0.4)
0.2 (0.7) 0.1
(0.4)
0.1 (0.6)
1Community-treated exacerbation consisting of a general practice visit plus a course of prednisolone 40mg once daily for 5 days and co-amoxiclav
875mg/125mg twice a day for 7 days.
Abbreviations: GP: general practitioner; ED: emergency department; SD: standard deviation; NL, Netherlands; SK, South Korea
doi:10.1371/journal.pone.0152618.t002
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The majority of patients (range 81% in Japan to 97% in Mexico) reported taking a prescrip-
tion medication for COPD during the past year (Table 3). With respect to prescribing patterns
of individual medications, there were wide variations across countries. Of note, patients in Rus-
sia and South Korea reported the most frequent use of over the counter and herbal remedies
(Russia [67%], South Korea [35%]).
Direct costs
The annual direct cost of COPD per patient ranged from $504 in South Korea to $9,981 in the
USA (Fig 1). The breakdown of direct costs varied across countries. In five countries inpatient
hospitalisations was the largest contributor to direct costs: France [54%], Germany [53%],
Spain [50%], the USA [33%], and South Korea [26%]) (Fig 1). General Practitioner visits con-
tributed substantially to the direct costs in Mexico (30%), Japan (28%) and the UK (26%) whilst
specialist visits contributed at least one quarter of the direct costs in Japan (28%), the UK
(26%), and the USA (26%). Home oxygen therapy accounted for the largest individual direct
costs in Brazil (28%), Russia (33%), France (30%), and Italy (40%). Prescription medication
costs for COPD accounted for between 4 and 33% of costs across countries, being the lowest in
Table 3. Proportion of patients (%) reporting treatment with COPDmedications, home oxygen use, and influenza vaccination: Continuing to Con-
front COPD International Patient Survey, 2012–13.
USA
n = 1,001
Mexico
n = 328
Brazil
n = 300
France
n = 300
Germany
n = 300
Italy
n = 302
Spain
n = 303
UK
n = 305
NL
n = 303
Russia
n = 301
Japan
n = 300
SK
n = 300
Prescription medication use (%)
Any prescription
medication for
COPD in the
past year
92 97 93 80 95 95 94 95 93 90 81 91
SABA and/or
SAMA
63 56 51 54 46 35 46 60 49 25 20 7
LABA 2 6 7 17 28 5 9 10 13 12 8 2
LAMA 27 8 12 10 22 12 26 21 28 1 21 7
ICS 12 12 10 20 17 16 11 17 28 20 20 7
ICS/LABA 47 0 18 7 24 23 36 27 50 21 38 20
Xanthines 2 7 4 3 9 1 3 2 1 16 20 5
Roflumilast 1 0 3 0 3 2 1 0 0 8 0 3
Other COPD-
related
prescription
medications1
28 77 57 32 34 37 43 32 20 80 46 62
Over the
counter/herbal
remedies
14 24 16 5 32 5 8 7 18 67 8 35
Influenza
vaccination in
the past year
67 57 51 41 45 47 56 66 70 9 46 80
Home oxygen
therapy use in
the past year
27 17 16 20 8 12 13 14 6 7 5 4
1Includes: oral and systemic corticosteroids, antibiotics, cough medicines, leukotriene receptor antagonists.
Abbreviations: SABA, short acting beta-2 agonists; SAMA, short acting anti-muscarincs; LAMA, long acting anti-muscarincs LABA, long acting beta-2
agonists; ICS, in haled corticosteroid; NL, Netherlands; SK, South Korea
doi:10.1371/journal.pone.0152618.t003
Economic Impact of COPD in 12 Countries
PLOS ONE | DOI:10.1371/journal.pone.0152618 April 19, 2016 7 / 15
France (4%), Mexico (8%) and Japan (9%), and the highest in Brazil (24%), Russia (24%) and
the Netherlands (33%).
Lost work productivity and indirect costs
The proportion of working age patients completely prevented from working due to their
COPD ranged from 6% to 52% across countries with the highest proportions reported in the
UK and the USA (52%) and the lowest (10%) reported in Italy, Russia and Japan (S1 Fig).
Patients reporting a limited ability to work ranged from 11% (Brazil and the Netherlands) to
28% (Germany), with the majority of countries falling within the range 11% to 19% (S1 Fig).
The annual indirect cost of COPD ranged from $979 (Russia) to $20,844 (the USA) (Fig 2).
Indirect costs calculated using the friction cost method were around a quarter of those calcu-
lated using the human capital approach (Table D in S1 Supporting information).
Total societal costs
The calculated annual societal per patient cost of COPD varied widely across countries, ranging
from $1,721 in Russia to $30,826 in the USA (Fig 2). The indirect cost of COPD exceeded the
direct cost in all countries except for France, where indirect costs per patient were $2,277 and
direct costs per patient were $3,406. Indirect costs in Brazil, Germany, the UK, the Netherlands
Fig 1. Annual direct costs per patient of COPD and percentage breakdown by cost type: Continuing to Confront COPD International Patient
Survey, 2012–13. Additional costs not shown: Nursing visits: NL (1%); Influenza vaccination: Brazil (2%); SK (2%); NL (1%); Abbreviations: USA, United
States of America, UK, United Kingdom, NL, Netherlands; SK, South Korea
doi:10.1371/journal.pone.0152618.g001
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and South Korea comprised over 80% of the total societal costs. A sensitivity analysis of total
societal costs using purchasing power parities instead of exchange rates demonstrated higher
per patient costs of COPD in Mexico, Brazil, Russia, Spain, and South Korea, and similar or
slightly lower costs in the remaining countries outside of the USA (Fig 3). However, the order
of magnitude of overall societal costs across countries remained largely the same.
The total societal costs per patient were greater in patients who reported increased levels of
breathlessness (mMRC2), greater impact on health status (CAT score>20), and perceived
themselves to have more severe COPD, than in those reporting less symptoms and less severe
disease (Fig 4). These findings were consistent across all countries. Patients who reported hav-
ing two or more comorbidities were slightly more costly than patients with none or one comor-
bidity, across most countries (an exception was France where costs were similar) (Fig 4).
Discussion
This analysis of data from the Continuing to Confront COPD International Patient Survey
evaluated the economic impact of COPD in a global population of patients across 12 countries.
This dataset provides one of the largest global cost of illness evaluations to date and, impor-
tantly, allows for a comparison with the original Confronting COPD Survey, enabling a study
of the changing economic impact of COPD over the last decade.
The current survey showed that the economic burden of COPD is considerable in all coun-
tries studied. The annual societal costs per patient covered a wide span ranging from $1,721
(Russia) to $30,826 (USA); however costs for the majority of countries fell within the
Fig 2. Annual societal costs per patient of COPD in each country (using exchange rates): Continuing to Confront COPD International Patient
Survey, 2012–13. Abbreviations: USA, United States of America, UK, United Kingdom, NL, Netherlands; SK, South Korea
doi:10.1371/journal.pone.0152618.g002
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approximate range of $4,000-$11,000. The largest direct cost associated with COPD in 5 of the
12 countries was attributed to hospitalisations. Other healthcare resources that made the larg-
est contribution to COPD direct costs were: home oxygen therapy (3 countries), GP or special-
ist visits (equal contribution in 2 countries), GP visits (1 country), and medication costs (1
country). Indirect costs including productivity loss were several times that of direct costs in
many countries including the USA, Germany, the UK, the Netherlands and South Korea. This
highlights the “hidden” burden of COPD often ignored by decision makers whilst making pol-
icy decisions.
The differing local unit costs of healthcare services in each country had limited impact on
the variability across different countries as shown by consistency in costs estimated using
exchange rates and purchasing power parities. Variability in the COPD patients surveyed
across multiple countries also had limited impact on societal costs with no consistent pattern
observed. For example, the USA had high proportion of severe/very severe COPD patients and
patients with two or more comorbidities consistent with high direct COPD costs. In contrast,
Japan had high proportion of patients with mild disease and yet had the second highest direct
costs. Direct costs were likely to be driven by healthcare systems and patients’ access to health-
care. Developed countries where access to COPD care was often free at the point of delivery
tended to have higher direct costs. Patients in these countries also tended to have high indirect
costs, mainly driven by higher national per capita incomes. Other factors influencing variations
in cost data could be those related to cultural and healthcare practices differences. Patients in
Japan reported the lowest levels of symptoms but had one of the highest proportions treated
under specialist care.
Fig 3. Annual societal per patient cost using exchange rates (Nov 2012 to May 2013) and Purchasing Power Parities (2013) (US$): Continuing to
Confront COPD International Patient Survey, 2012–13. Abbreviations: USA, United States of America, UK, United Kingdom, NL, Netherlands; SK, South
Korea
doi:10.1371/journal.pone.0152618.g003
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A consistent finding across countries was the association between increased reported bur-
den of COPD (breathlessness, symptoms and comorbidities) and greater total societal costs per
patient. These findings are consistent with those reported in previous international surveys of
COPD patients in developed and developing countries [6–8], and in a recent systematic review
highlighting the substantial humanistic and economic burden of symptomatic COPD [18].
This further emphasizes the opportunity to impact the economic burden of COPD through
better symptom control and the effective management of comorbidities. There were no consis-
tent differences between costs in current smokers, former smokers and those who had never
smoked (data not shown). This differed from the original Confronting COPD survey which
reported that former smokers were more costly to healthcare systems than current smokers,
and which the authors suggested could have been related to smokers quitting upon developing
disease symptoms or immediately after diagnosis of smoking-related diseases [6].
Comparing the cost of COPD across individual studies, a USA medical expenditure survey
in 2010 reported an average per person medical expenditure on COPD to be $9,800 (compared
with $30,826 in the current survey) which included direct medical expenses and costs due to
work loss (absenteeism), but not costs due to lost work productivity (presenteeism) which were
included in the Continuing to Confront COPD Survey [19]. A prospective one-year follow-up
study of primary care patients in Spain from 1996 to 1997 reported direct annual costs of
$1,876, compared with $3,570 in the current survey, and concurring with the present findings,
the biggest single contributor to costs was hospitalisations [20]. Nishimura et al used an eco-
nomic model to assess the economic impact of COPD in Japan using data published between
1990 and 2002, and estimated the average annual total cost per patient for moderate/severe
COPD to be US$3,694, compared with $9,893 in the Continuing to Confront COPD Survey,
although 80% of costs were attributed to direct costs and 20% to indirect costs while the cost
contribution was relatively equal in the current analysis [21]. Interestingly, the Nishimura
study reported that outpatient visits accounted for 50% of direct costs, very similar to the find-
ings in the current survey. A 2009 study conducted in the South Korean National Health Insur-
ance database estimated direct costs per patient of $2,803, greater than the $504 in the current
survey, although the Kim et al study population were receiving at least two COPD medications
and also included intensive care and tertiary medical care costs [22]. A cross-sectional survey
of physician-diagnosed COPD patients in Brazil, China, Germany, Turkey, the UK and the
USA, reported lower indirect costs due to working hours lost than that shown in the Continu-
ing to Confront COPD survey, but the magnitude of losses showed a similar pattern by country
with the greatest impacts reported in the UK and the USA [6]. However these cross-study com-
parisons are limited due to differences in methodologies, populations studied and the type of
economic evaluation used.
A main strength of the Continuing to Confront COPD Survey is that it allows for the assess-
ment of change in the economic burden of COPD over a decade since the original Confronting
COPD Survey was undertaken. In countries that participated in both surveys (France, Italy, the
Netherlands, Spain, the UK and the USA), the annual societal costs per patient has increased
above inflation in all countries [6]. The original Confronting COPD International Survey
reported that the main driver of direct costs was inpatient hospitalisations in 5 out of 7 coun-
tries surveyed, and that the country incurring the biggest direct costs was the USA, the latter
being consistent with the updated findings. The original survey reported high direct costs in
Fig 4. Annual societal costs per patient using exchange rates of COPD stratified by disease and patient characteristics: Continuing to Confront
COPD International Patient Survey, 2012–13. (A) By mMRC grade. (B) By CAT score. (C) By self-perceived severity of COPD. (D) By Comorbidities.
Abbreviations: CAT, COPD Assessment Test; mMRC, modified Medical Research Council Scale; USA, United States of America, UK, United Kingdom, NL,
Netherlands; SK, South Korea
doi:10.1371/journal.pone.0152618.g004
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Spain and low direct costs in the Netherlands which was also observed in the current analysis.
In contrast, while France had the lowest direct costs in the original survey, it is among the high-
est for Europe in the current survey. This may be due to a higher contribution of inpatient hos-
pitalisations to the French direct costs in the current survey compared to a decade ago. There
was also consistency between surveys in the specific countries reporting high levels of indirect
costs (USA, UK and the Netherlands). However, the use of the WPAI questionnaire in the cur-
rent survey may have contributed to the observation that the indirect costs were higher than
direct costs in nearly all countries, which is in contrast to the original Confronting COPD sur-
vey. Whilst the friction cost method is not widely used outside of the Netherlands [17], apply-
ing it as a scenario analysis for all countries resulted in a ratio of indirect to direct costs that
more closely resembled what was seen in the original survey (where the friction cost method
was only applied in the Netherlands).
In addition to historical comparison, it can also be of interest to understand COPD costs in
the context of other common chronic diseases. A review by Muka et al ranked the costs associ-
ated with COPD to be lower than those for cancer and cardiovascular disease and higher than
those associated with diabetes [23]. For example, direct costs for type 2 diabetes mellitus based
on a systematic review of the literature from 2001 to 2014 ranged from $242 to $11,917 and
indirect costs ranged from $45 to $16,914 [24]. We found indirect costs were higher than direct
costs across all countries except for France, which has also been suggested in other disease
areas. A literature review investigating the economic impact of a range of non-communicable
diseases (including coronary heart disease, stroke, type 2 diabetes mellitus, cancer, COPD and
chronic kidney disease) on work productivity, reported that people with diabetes, COPD and
survivors of breast and lung cancer were at the highest risk of impact on work productivity
[25].
The case definition used in this study included a variety of conditions reflecting how COPD
may be diagnosed in different countries, including both physician-diagnosed disease and
chronic bronchitis based on symptoms. Diagnosis of COPD based on symptoms overcame
some of the problems associated COPD under-diagnosis and with physicians using alternative
diagnosis terms when speaking to their patients. We accept that it is possible that some patients
with lung diseases other than COPD may have been included under this definition, but symp-
tom based COPD represented only 10% of the final sample. Another limitation of the Continu-
ing to Confront COPD International Patient Survey is that outcomes were self-reported and
could not be clinically verified, although this was partly mitigated by the use of validated
patient reported outcome instruments. Furthermore, resource use was derived indirectly from
survey responses and assumptions inevitably needed to be made in order to bridge survey
responses to resource counts. A fixed cost was assigned to each type of resource use based on
information from local health economics experts in each participating country, global datasets
or local prescribing data on medication sales. The accuracy of these cost estimates was funda-
mental to the resultant estimated costs in each country.
The survey attempted to collect a variety of costs attributable to COPD, however, it was not
possible to capture every single resource use parameter (e.g. pulmonary rehabilitation, lung
volume reduction surgery) or monetise every parameter recorded (e.g. cost of all medications
or all healthcare professional visits). Costs of out-of- pocket expenses such as non-prescription
medication were also excluded. This survey did not include indirect costs due to caregiver
work loss, suggesting that indirect costs of COPD may be even higher than that reported. In
addition, if retirement ages increase in the future, the burden due to early retirement could also
be higher as was suggested by Fletcher et al in the COPD Uncovered International Survey in a
working age COPD population [8]. Overall, this may lead to potential underestimation of the
total economic burden attributable to COPD.
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Conclusion
This economic analysis of the Continuing to Confront COPD International Patient Survey
showed that COPD continues to place a high economic burden on the healthcare system and
society in all countries studied. Indirect costs were higher in most countries and, patients with
breathlessness, symptoms and comorbidities experienced higher costs. Attempts to reduce the
economic burden will require interventions aimed at delaying the progression of disease, pre-
venting exacerbations, optimising medication usage and reducing the risk of comorbidities in
patients with COPD. In addition, strategies to allow COPD patients to remain in work are
important for addressing the substantial wider societal costs.
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